TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

Inclusion Criteria: * Adolescents aged ≥ 12 to 17 years, inclusive, and men and women aged ≥ 18 years. * Participants diagnosed with atopic dermatitis (AD) as defined by the Hanifin and Rajka criteria. * AD duration of at least 2 years. * Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at Screening and Baseline (VC Period) and 0 to 4 at Week 8 (LTS Period). * Participants with percentage body surface area (%BSA) (excluding scalp) of AD involvement of 3% to 20% at Screening and Baseline (VC Period) and 0% to 20% at Week 8 (LTS Period). * Participants who agree to discontinue all agents used to treat AD from Screening through the final follow-up visit. * Participants who have at least 1 "target lesion" that measures approximately 10 cm\^2 or more at Screening and Baseline. Lesion must be representative of the participant's disease state and not be located on the hands, feet, or genitalia. * Willingness to avoid pregnancy or fathering of children. Exclusion Criteria: * Unstable course of AD (spontaneously improving or rapidly deteriorating) as determined by the investigator in the 4 weeks prior to Baseline. * Concurrent conditions and history of other diseases: * Immunocompromised. * Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before Baseline. * Active acute bacterial, fungal, or viral skin infection within 1 week before Baseline. * Any …